Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer

Y Togashi, K Masago, S Fujita, Y Hatachi, A Fukuhara… - Lung cancer, 2011 - Elsevier
PURPOSE: The maximum tolerated dose (MTD) of erlotinib (150mg) is the approved daily
dose. In contrast, the approved daily dose of gefitinib (250mg) is only one-third of its MTD …
被引用次数：38 相关文章

Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer

Y Togashi, K Masago, S Fujita… - Lung cancer …, 2011 - pubmed.ncbi.nlm.nih.gov
Purpose The maximum tolerated dose (MTD) of erlotinib (150 mg) is the approved daily
dose. In contrast, the approved daily dose of gefitinib (250 mg) is only one-third of its MTD …

[引用][C] Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer

Y Togashi, K Masago, S Fujita, Y Hatachi, A Fukuhara… - Lung Cancer, 2011 - cir.nii.ac.jp
Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in
Japanese patients with non-small cell lung cancer | CiNii Research CiNii 国立情報学研究所 …

Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.

Y Togashi, K Masago, S Fujita, Y Hatachi… - Lung Cancer …, 2011 - europepmc.org
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in
Japanese patients with non-small cell lung cancer. - Abstract - Europe PMC Sign in | Create …

[引用][C] Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer

Y TOGASHI, K MASAGO, S FUJITA, Y HATACHI… - Lung …, 2011 - pascal-francis.inist.fr
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in
Japanese patients with non-small cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal …

Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer

Y Togashi, K Masago, S Fujita, Y Hatachi… - Lung …, 2011 - lungcancerjournal.info
Purpose The maximum tolerated dose (MTD) of erlotinib (150mg) is the approved daily
dose. In contrast, the approved daily dose of gefitinib (250mg) is only one-third of its MTD …

Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer

Y Togashi, K Masago, S Fujita, Y Hatachi… - Lung …, 2011 - okayama.elsevierpure.com
Purpose: The maximum tolerated dose (MTD) of erlotinib (150. mg) is the approved daily
dose. In contrast, the approved daily dose of gefitinib (250. mg) is only one-third of its MTD …

Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer

Y Togashi, K Masago, S Fujita, Y Hatachi, A Fukuhara… - Lung Cancer, 2011 - infona.pl
The maximum tolerated dose (MTD) of erlotinib (150mg) is the approved daily dose. In
contrast, the approved daily dose of gefitinib (250mg) is only one-third of its MTD …

Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer

Y Togashi, K Masago, S Fujita, Y Hatachi… - Lung …, 2011 - okayama.elsevierpure.com
Purpose: The maximum tolerated dose (MTD) of erlotinib (150. mg) is the approved daily
dose. In contrast, the approved daily dose of gefitinib (250. mg) is only one-third of its MTD …